Navigation Links
Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
Date:10/16/2008

Collaboration Brings Cooperative Group Level Radiation Therapy Trials to US

Oncology Affiliates' Patients for First Time

HOUSTON, Oct. 16 /PRNewswire/ -- The Radiation Therapy Oncology Group (RTOG) and US Oncology, Inc. today announced they have entered into a collaboration to increase patient access to national cancer clinical trials with a radiation focus in the community setting.

The collaboration means patients receiving cancer care at practices affiliated with US Oncology have access to RTOG trials for disease sites including brain, head & neck, lung, gastrointestinal, genitourinary, cervix, and breast cancers. RTOG trials focus on testing the integration of radiation therapy with new systemic therapies and surgery.

The collaboration also marks the first time US Oncology, as a network of member practices, has participated in cooperative group trials in radiation oncology. In addition, US Oncology is the first multi-state, national organization to become an affiliate member of RTOG. Current members include large regional practices and academic practices with several facilities in metropolitan areas.

"Our collaboration with US Oncology and its network of member practices is attractive due to the organization's strong commitment to clinical trial participation, leadership and accrual," said Walter Curran, MD, Group Chairman of RTOG and professor and chairman of the Department of Radiation Oncology of Emory University School of Medicine. Dr. Curran also serves as Chief Medical Officer of the Winship Cancer Center at Emory University. "We were confident their track record as a multi-site organization with significant accruals in a variety of clinical trials would be a good fit," said Dr. Curran.

Following infrastructure development to centralize the IRB, data collection, reporting, credentialing and quality assurance to operate as a network, US Oncology was granted affiliate member status in the RTOG late last
'/>"/>

SOURCE US Oncology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
3. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
4. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
5. Carrington and DaySpring Pharma Extend and Formalize Agreement for Distribution of Diabetic and Radiation Products Into Physician Market
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Synchrotron radiation illuminates how babies protective bubble bursts
8. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
9. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
10. FDA Clears Expanded Use of Xofts Axxent(R) Electronic Brachytherapy System for all Radiation Therapy Indications
11. CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncology Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , Mar. 04, 2015 Research and Markets ... addition of Jain PharmaBiotech,s new report "Biomarkers ... offering. This report follows the ... that can be objectively measured and evaluated as ... as well as pharmacological responses to a therapeutic ...
(Date:3/4/2015)... March 4, 2015 AcelRx Pharmaceuticals, Inc. ... company focused on the development and commercialization of ... breakthrough pain, today announced that it will release ... market close on Monday, March 9th, 2015. AcelRx ... 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) ...
(Date:3/4/2015)... , March 4, 2015 ... Paris en décembre 2011, ... SARAH   », qui compare   l ... le   sorafénib dans le carcinome hépatocellulaire avancé, ... cancer du foie avancé   ; les résultats ...
(Date:3/3/2015)... March 03, 2015 Experts and industry ... for one event: the Alltech REBELation exploring innovation, inspiration ... 17-20. Now in its 31st year, Alltech’s annual international ... countries, and the opportunity to join the REBELation at ... at 11:59 p.m. EST, at which point the standard ...
Breaking Biology Technology:Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
... those that will be presented by researchers from the ... American Physical Society meeting, March 10-14, 2008, at the ... the content of each talk is embargoed until the ... the research described below was funded by the Office ...
... Acquisition of PDL BioPharma,s Antibody Manufacturing ... Facility has ... A/S (OMX: GEN) and PDL BioPharma, Inc.,(Nasdaq: PDLI ) today ... acquired PDL,s antibody manufacturing,facility located in Brooklyn Park, Minnesota, USA for ...
... 13 ,Cellectis SA (NYSE: ALCLS ), ... announced today that it filed a patent ... United States District Court for the,Eastern District ... declaration that,by making and selling certain meganucleases, ...
Cached Biology Technology:News from the March 2008 American Physical Society Meeting 2News from the March 2008 American Physical Society Meeting 3News from the March 2008 American Physical Society Meeting 4News from the March 2008 American Physical Society Meeting 5Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility 2Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology 2Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology 3Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology 4
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America recently ... for carbon nanotube (CNT) macrostructures, including sheets, yarns and ... (UTD). Leveraging the vast industrial resources of ... Japan , Lintec of America is forming the ... TX , focusing on scaling up the manufacturing ...
(Date:2/5/2015)... --NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... on the growing mobile commerce market, announces the launch ... part of its 2015 marketing and branding initiatives for ... consumer website for Wocketwallet.com earlier this month. ... "Our new corporate website naturally showcases our premiere consumer ...
(Date:2/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ) ... Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, ... their offering. , In global ... anticipated to overtake North America ... towards IT security, government biometric based projects such ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... Director of the Grow Clinic for Children at Boston ... Boston University School of Medicine (BUSM), has received a ... Health to study the long-term impacts of intrauterine cocaine ... The project, entitled Prenatal Cocaine Exposure: Young Adult Follow-Up, ...
... sheep infected with scrapie a neurological disorder similar ... glow when they,re hit with blue excitation light, according ... Jacob Petrich. The findings suggest technologies and techniques ... transmissible spongiform encephalopathies, progressive and fatal neurological diseases such ...
... Illinois chemists have developed a simple sensor to detect ... to inexpensive, easy-to-use devices for luggage and passenger screening ... a high-powered explosive that in recent years has been ... prepare from readily available components and has been difficult ...
Cached Biology News:Iowa State, USDA researchers discover eye test for neurological diseases in livestock 2Iowa State, USDA researchers discover eye test for neurological diseases in livestock 3Sniffing out shoe bombs: A new and simple sensor for explosive chemicals 2
ANTI END CEL LUNG AG...
EGTA, 50 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
RABBIT ANTI NEOPTERIN...
Biology Products: